Trial Profile
A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 29 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 29 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 31 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.